Literature DB >> 29490557

Intralesional bleomycin A5 injection for the treatment of nasal polyps through inducing apoptosis.

Peng Tian1, Fan Wu1, Jingyi Wang1, Huashuang Ou1, Xiang Liu1, Qiujian Chen1, Hua Dang1, Yiqing Zheng1, Xianghong Zhang2, Hua Zou1.   

Abstract

CONCLUSION: An intralesional bleomycin A5 (BLE) injection might be used as an alternative therapy for eosinophilic-type nasal polyps (NPs). BLE-induced apoptosis might play an important role in shrinkage of NPs.
OBJECTIVES: The aim of this study is to determine the effect and explore the possible role of apoptosis in shrinkage of NPs.
METHODS: Twenty-nine patients with eosinophilic-type NPs experienced repeated local injection of BLE. The recurrence rate of this group was obtained. The mechanism of BLE treatment was investigated through an in vitro experiment. Nasal polyp tissues were treated with BLE. The apoptotic activity was detected by the presence of DNA smear and test of terminal deoxynucleotidyl transferase dUTP nick end labeling. The caspase-8 and PARP were examined through immunohistochemistry and Western blotting.
RESULTS: After several local injections of BLE, the nasal polyp tissues decreased and then disappeared. During follow-up of 3 years the recurrence rate of this group was significantly lower than another one treated with operation plus medicine treatment. Apoptosis in BLE-treated tissue was prominently detected in the infiltrating inflammatory cells. The expression of PARP and casp-8 were increased in BLE-treated nasal polyp tissue compared with PBS-treated tissue.

Entities:  

Keywords:  Nasal polyp; apoptosis; bleomycin A5

Mesh:

Substances:

Year:  2018        PMID: 29490557     DOI: 10.1080/00016489.2017.1380312

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  1 in total

1.  High PI3K/mTOR and low MAPK/JNK activity results in decreased apoptosis and autophagy in nasal polyposis.

Authors:  Fatma Simsek; Erdem Eren; Selen Bahceci; Ibrahim Aladag
Journal:  Braz J Otorhinolaryngol       Date:  2020-01-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.